A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Sprifermin (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms FORWARD
  • Sponsors EMD Serono
  • Most Recent Events

    • 08 Nov 2017 Results of two-year primary analysis data presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 04 Nov 2017 According to a Merck KGaA media release, Dr. Marc C. Hochberg, Division Head, Rheumatology and Clinical Immunology, University of Maryland School of Medicine is the primary investigator of the study.
    • 04 Nov 2017 Primary endpoint has been met. (Change from Baseline in cartilage thickness in the total femorotibial joint as evaluated by MRI at 2 years [ Time Frame: Baseline and 2 years ]), according to a Merck KGaA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top